CN114144425B - 用于阿尔茨海默症的基因治疗 - Google Patents

用于阿尔茨海默症的基因治疗 Download PDF

Info

Publication number
CN114144425B
CN114144425B CN202080052274.9A CN202080052274A CN114144425B CN 114144425 B CN114144425 B CN 114144425B CN 202080052274 A CN202080052274 A CN 202080052274A CN 114144425 B CN114144425 B CN 114144425B
Authority
CN
China
Prior art keywords
leu
disease
val
composition
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080052274.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114144425A (zh
Inventor
沈洁
R·J·凯莱赫三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
General Hospital Corp
Original Assignee
The Brigham and Women's Hospital Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc, General Hospital Corp filed Critical The Brigham and Women's Hospital Inc
Publication of CN114144425A publication Critical patent/CN114144425A/zh
Application granted granted Critical
Publication of CN114144425B publication Critical patent/CN114144425B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080052274.9A 2019-05-24 2020-05-21 用于阿尔茨海默症的基因治疗 Active CN114144425B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852716P 2019-05-24 2019-05-24
US62/852,716 2019-05-24
PCT/US2020/034040 WO2020242892A1 (en) 2019-05-24 2020-05-21 Gene therapy for alzheimer's disease

Publications (2)

Publication Number Publication Date
CN114144425A CN114144425A (zh) 2022-03-04
CN114144425B true CN114144425B (zh) 2025-05-13

Family

ID=73553511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052274.9A Active CN114144425B (zh) 2019-05-24 2020-05-21 用于阿尔茨海默症的基因治疗

Country Status (8)

Country Link
US (1) US12540334B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976637A4 (cg-RX-API-DMAC7.html)
JP (1) JP7686573B6 (cg-RX-API-DMAC7.html)
CN (1) CN114144425B (cg-RX-API-DMAC7.html)
AU (1) AU2020285638A1 (cg-RX-API-DMAC7.html)
CA (1) CA3141712A1 (cg-RX-API-DMAC7.html)
IL (1) IL288266A (cg-RX-API-DMAC7.html)
WO (1) WO2020242892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019272848A1 (en) 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
AU2020393917A1 (en) 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
JP7849078B2 (ja) * 2022-01-29 2026-04-21 シャンハイ、レイジング、ファーマシューティカル、カンパニー、リミテッド Tpkを発現する組換えウイルスおよびアルツハイマー病の処置におけるその使用
JP2025527208A (ja) * 2022-07-25 2025-08-20 ヴィコ・セラピューティクス・ベー・フェー Appの異常なプロセシングに関連する疾患又は病態の治療用アンチセンスオリゴヌクレオチド

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JPH10501686A (ja) 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのdnaのaav仲介送達
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
WO1997027296A1 (en) 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
AR020107A1 (es) 1998-07-09 2002-04-10 Boehringer Ingelheim Pharma Metodo para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, las sustancias identificables con dicho metodo, el usode estas ultimas en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y las composiciones farmaceuticas que
JP2002520055A (ja) 1998-07-16 2002-07-09 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトプレセニリン関連タンパク質
US6979537B2 (en) 2000-01-10 2005-12-27 Scios, Inc. Methods for identifying inhibitors of neuronal degeneration
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7271313B2 (en) 2003-04-09 2007-09-18 The Brigham And Women's Hospital, Inc. Presenilin-deficient mouse model of age-dependent neurodegeneration and cognitive loss
CA2528963A1 (en) 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
WO2005037226A2 (en) 2003-10-17 2005-04-28 Georgia Tech Research Corporation Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders
CA2541523A1 (en) 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
WO2005096781A2 (en) 2004-04-06 2005-10-20 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using rna interference
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
CN101031658A (zh) 2004-05-26 2007-09-05 罗塞塔金诺米克斯有限公司 病毒和病毒相关mirna及其用途
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2009042727A1 (en) 2007-09-24 2009-04-02 The Johns Hopkins University Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin
AU2010316982B2 (en) 2009-11-09 2013-09-12 Genepod Therapeutics Ab Novel viral vector construct for neuron specific continuous DOPA synthesis in vivo
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
CN103816540B (zh) 2012-11-16 2018-01-02 中国科学院上海生命科学研究院 降低β‑抑制蛋白1与APH‑1蛋白的结合的物质在制备防治神经退行性疾病药物中的应用
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
WO2015006743A1 (en) 2013-07-12 2015-01-15 The Children's Hospital Of Philadelphia Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US10350245B2 (en) * 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
EP3270960A4 (en) 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3025626A1 (en) 2016-05-27 2017-11-30 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger rna
WO2018045022A1 (en) 2016-08-30 2018-03-08 University Of South Florida Adipose derived stem cell exosomes and uses thereof
WO2018140532A1 (en) 2017-01-24 2018-08-02 Fred Hutchinson Cancer Research Center Systems and methods for hematopoietic cell expansion utilizing hydrogels
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
US11015204B2 (en) * 2017-05-31 2021-05-25 Arcturus Therapeutics, Inc. Synthesis and structure of high potency RNA therapeutics
US11512327B2 (en) * 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
AU2019272848A1 (en) 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
AU2020393917A1 (en) 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
EP4096786A4 (en) 2020-01-31 2024-04-10 Paros Bio, Inc. GENE THERAPY FOR NEURODEGENERATIVE DISORDERS USING POLYNUCLEOTIDE SILENCING AND REPLACEMENT

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Homo sapiens presenilin 1 (PSEN1), transcript variant 1, mRNA;NCBI Reference Sequence: NM_000021.3;《NCBI》;20181028;全文 *
Homo sapiens presenilin 1 (PSEN1), transcript variant 2, mRNA;NCBI Reference Sequence: NM_007318.2;《NCBI》;20190521;全文 *
NCBI Reference Sequence: NM_000021.3.Homo sapiens presenilin 1 (PSEN1), transcript variant 1, mRNA.《NCBI》.2018,全文. *
NCBI Reference Sequence: NM_007318.2.Homo sapiens presenilin 1 (PSEN1), transcript variant 2, mRNA.《NCBI》.2019,全文. *

Also Published As

Publication number Publication date
JP7686573B2 (ja) 2025-06-02
US12540334B2 (en) 2026-02-03
WO2020242892A1 (en) 2020-12-03
IL288266A (en) 2022-01-01
CN114144425A (zh) 2022-03-04
JP2022533451A (ja) 2022-07-22
US20220235374A1 (en) 2022-07-28
JP7686573B6 (ja) 2025-07-04
EP3976637A1 (en) 2022-04-06
CA3141712A1 (en) 2020-12-03
EP3976637A4 (en) 2023-07-12
AU2020285638A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
JP7587423B2 (ja) アルツハイマー病のための遺伝子治療
JP7686573B6 (ja) アルツハイマー病のための遺伝子治療
US20240327477A1 (en) Compositions and methods for the treatment of tdp-43 proteinopathies
CN113557243A (zh) 用于神经变性疾病的基因疗法
US20230234997A1 (en) Compositions and Methods for the Treatment of Synucleinopathies
SG11202108568YA (en) Dna-binding domain transactivators and uses thereof
CN116670291A (zh) 用于神经退行性疾病的基因疗法
CA3140507A1 (en) Insulin gene therapy
EP4584383A1 (en) Beta-hexosaminidase vectors
CN121693571A (zh) 用于治疗中枢神经系统蛋白质病的重组腺相关病毒载体
AU2024305531A1 (en) Materials and methods for the treatment of neurofibromin 1 mutations and diseases resulting therefrom
HK40092059A (en) Compositions and methods for the treatment of synucleinopathies
AU2021367952A1 (en) Compositions and methods for the treatment of alzheimer's disease
CN120400250A (zh) 表达myo7a蛋白的双载体系统及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant